Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies


January 3, 2019

Today we announced that we have entered into a strategic research collaboration with Arbor Biotechnologies focused on the discovery of novel proteins including DNA endonucleases to advance the development of potential new gene-editing therapies for cystic fibrosis and four other diseases to be selected later.  Arbor has developed a protein biodiscovery platform that includes a comprehensive set of technologies and techniques, integrating machine learning, genome sequencing, gene synthesis, and high-throughput screening that will augment Vertex’s efforts to develop gene-editing approaches for the treatment of serious diseases.